Figure 1
From: Evidence for oligodendrocyte progenitor cell heterogeneity in the adult mouse brain
Validation of PDGFRα-CreER; R26-EYFP reporter mouse. (A) Timeline of tamoxifen injections and tissue harvest used to validate YFP expression and titrate optimal tamoxifen dosing paradigm. (B) Immunofluorescence of PDGFRα (red), Olig2 (blue), and YFP (green) in PDGFRα-CreER; R26-eYFP mice receiving no tamoxifen injections (− Tamoxifen) or 2 tamoxifen injections (+ Tamoxifen). Arrows represent OPCs expressing YFP and arrowheads represent OPCs lacking YFP expression. Scale bar = 30 µm. (C) Percentage of OPCs (PDGFRα+/Olig2+) that also express YFP following 0, 1, 2, or 3 tamoxifen injections. N = 3 independent experiments, n = 2–3 per group. Error bars represent SEM. (D) Proportion of YFP+ cells identified as OPCs (PDGFRα+/Olig2+), Oligodendrocytes (OLG, PDGFRα−/Olig2+), or neither of these cell types (Other, PDGFRα+/Olig2− or PDGFRα−/Olig2−) following 2 tamoxifen injections. N = 2 independent experiments, n = 3 samples. Data quantified in (C,D) include images from the prefrontal cortex, hippocampus, and corpus callosum.
